Zobrazeno 1 - 10
of 660
pro vyhledávání: '"Neal D. Shore"'
Publikováno v:
Therapeutic Advances in Urology, Vol 16 (2024)
Non-muscle-invasive bladder cancer (NMIBC), which is restricted to the mucosa (stage Ta, carcinoma in situ (CIS)) or submucosa (stage T1), comprises 75% of bladder cancer diagnoses. Intravesical bacillus Calmette-Guérin (BCG) therapy is the standard
Externí odkaz:
https://doaj.org/article/dbaa94d06dab4b4cacb68ab3932ec2b7
Autor:
Mohamad Moussa, Mohamad Abou Chakra, Neal D. Shore, Athanasios Papatsoris, Yasser Farahat, Michael A. O’Donnell
Publikováno v:
Archivio Italiano di Urologia e Andrologia (2024)
Purpose: To understand the treatment plans suggested for BCG-unresponsive non-muscle invasive disease (NMIBC) patients in the Arab countries and therapeutic decisions applied for BCG-naive patients during BCG shortage time. Methods: A 10-minute onlin
Externí odkaz:
https://doaj.org/article/9c91914fb36a42a8ae93890e0f70d456
Autor:
Vikram M. Narayan, Joshua J. Meeks, Jørn S. Jakobsen, Neal D. Shore, Grannum R. Sant, Badrinath R. Konety
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Effective bladder-preserving therapeutic options are needed for patients with bacillus Calmette-Guérin unresponsive non–muscle-invasive bladder cancer. Nadofaragene firadenovec-vncg (Adstiladrin®) was approved by the US Food and Drug Administrati
Externí odkaz:
https://doaj.org/article/0de0014eb35148a0bbf4de0bf81ecb87
Autor:
Celestia S. Higano, Daniel J. George, Neal D. Shore, Oliver Sartor, Kurt Miller, Peter S. Conti, Cora N. Sternberg, Fred Saad, Juan Pablo Sade, Joaquim Bellmunt, Matthew R. Smith, Kumari Chandrawansa, Per Sandström, Frank Verholen, Bertrand Tombal
Publikováno v:
EClinicalMedicine, Vol 60, Iss , Pp 101993- (2023)
Summary: Background: Radium-223, a targeted alpha therapy, is approved to treat bone-dominant metastatic castration-resistant prostate cancer (mCRPC), based on significantly prolonged overall survival versus placebo and a favourable safety profile in
Externí odkaz:
https://doaj.org/article/ede8b4395fd74aa190c82bdfe489b529
Autor:
Fred Saad, Daniel J. George, Michael S. Cookson, Daniel R. Saltzstein, Ronald Tutrone, Alberto Bossi, Bruce Brown, Bryan Selby, Sophia Lu, Bertrand Tombal, Neal D. Shore
Publikováno v:
Cancers, Vol 15, Iss 19, p 4854 (2023)
Background: Relugolix is an oral GnRH receptor antagonist approved for men with advanced prostate cancer. Relugolix treatment has demonstrated an ability to lower testosterone to sustained castration levels in the phase 4 HERO study. Herein, we descr
Externí odkaz:
https://doaj.org/article/0e18f74c328349cda6822ae62b233f67
Autor:
Herjan J.T. Coelingh Bennink, Jeroen A. van Moorselaar, E. David Crawford, Erik P.M. Roos, Diederik M. Somford, Ton A. Roeleveld, Tjard D. de Haan, Harm H.E. van Melick, Yacov Reisman, Yvette Zimmerman, Gonnie van Osta, Jan Krijgh, Neal D. Shore, Fred Saad, Andrew V. Schally, Frans M.J. Debruyne
Publikováno v:
European Urology Open Science, Vol 28, Iss , Pp 52-61 (2021)
Background: Androgen deprivation therapy (ADT) for prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonists can be improved. Objective: To assess safety, the frequency and severity of hot flushes (HFs), bone health, and antitumor ef
Externí odkaz:
https://doaj.org/article/dc4f5a0c31044f3baa728ff536e9797f
Autor:
Neal D. Shore
Publikováno v:
European Urology Open Science, Vol 46, Iss , Pp 145-146 (2022)
Externí odkaz:
https://doaj.org/article/eff3a35c336943f0af7c34eab6392957
Autor:
Bilal Chughtai, Sirikan Rojanasarot, Kurt Neeser, Dmitry Gultyaev, Stacey L. Amorosi, Neal D. Shore
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 8, Iss 1 (2021)
**Background:** Benign prostatic hyperplasia (BPH) is one of the most prevalent and costly chronic conditions among middle-aged and elderly men. Prostatic urethral lift (PUL) and convective water vapor thermal therapy (WVTT) are emerging minimally in
Externí odkaz:
https://doaj.org/article/8361c207367c43c19116d714866f036c
Autor:
Fred Saad, Neal D. Shore
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Androgen deprivation therapy (ADT) is the foundation of treatment for patients with locally advanced, recurrent and metastatic prostate cancer, most commonly using luteinizing releasing hormone (LHRH) agonists. More recently, a new approach to ADT ha
Externí odkaz:
https://doaj.org/article/c00452a5dae7465192d2f14c2955f9b9
Autor:
Neil M. Schultz, Neal D. Shore, Simon Chowdhury, Laurence H. Klotz, Raoul S. Concepcion, David F. Penson, Lawrence I. Karsh, Hongbo Yang, Bruce A. Brown, Arie Barlev, Scott C. Flanders
Publikováno v:
BMC Urology, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background This analysis estimated the number needed to treat with enzalutamide versus bicalutamide to achieve one additional patient with chemotherapy-naïve metastatic castration-resistant prostate cancer who would obtain clinical benefit
Externí odkaz:
https://doaj.org/article/ac2303e9cda546ff9696e315c7ef9767